Easing the way to achieving target serum urate in people with gout: a non-inferiority strategy trial using an allopurinol dosing model. (The Easy-Allo study)

niversity of Otago0 个研究点目标入组 380 人开始时间: 2022年9月29日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•1. Age over 18 years
•2. Gout according to the 2015 ACR/EULAR criteria
•3. Serum urate greater than or equal to 0.36mmol/l (6mg/dl) AND
•-not taking allopurinol, but starting urate-lowering therapy strongly recommended in the 2020 ACR gout management guidelines (i.e. any of the following: greater than or equal to 2 gout flares/year, greater than or equal to 1 subcutaneous tophi, radiographic damage due to gout) OR
•-already taking allopurinol for gout at lower than predicted dose OR
•-already taking allopurinol but not regularly
•4. Agreeable to starting or continuing allopurinol
•5. Ability to give informed consent
•6. Ability to communicate via telephone

•1. Severe kidney disease with estimated glomerular filtration rate (eGFR) <30ml/min/1.73m2
•2. Contra-indication or previous intolerance to allopurinol
•3. Concomitant azathioprine, due to interactions with allopurinol
•4. HLA-B*5801 positive in high allele frequency populations (South East Asian and African), due to high risk of allopurinol hypersensitivity syndrome
•5. Female of childbearing age not on contraception
•5. Unstable co-morbid health conditions (e.g. NYHA stage 4 heart failure, recent myocardial infarction, advanced cancer)
•6. Dementia

发起方